50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:LPCN

Lipocine - LPCN News Today

$0.42
+0.03 (+7.12%)
(As of 09/28/2022 05:07 PM ET)
Add
Compare
Today's Range
$0.40
$0.43
50-Day Range
$0.39
$0.82
52-Week Range
$0.36
$1.89
Volume
352,654 shs
Average Volume
498,956 shs
Market Capitalization
$37.17 million
P/E Ratio
10.50
Dividend Yield
N/A
Price Target
N/A
Get Lipocine News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.



LPCN Media Mentions By Week

LPCN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LPCN
News Sentiment

0.50

0.72

Average
Medical
News Sentiment

LPCN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LPCN Articles
This Week

12

1

LPCN Articles
Average Week

SourceHeadline
MarketBeat logoLipocine Inc. (NASDAQ:LPCN) CEO Mahesh V. Patel Acquires 100,000 Shares
americanbankingnews.com - September 28 at 5:22 AM
finance.yahoo.com logoLipocine to Participate in the Cantor Neurology & Psychiatric Conference
finance.yahoo.com - September 27 at 3:11 PM
seekingalpha.com logoLipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking Alpha
seekingalpha.com - September 27 at 10:10 AM
MarketBeat logoLipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - September 27 at 2:22 AM
finance.yahoo.com logoLipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
finance.yahoo.com - September 26 at 6:43 PM
finance.yahoo.com logoLipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders
finance.yahoo.com - September 26 at 8:43 AM
finance.yahoo.com logoLipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo Finance
finance.yahoo.com - September 23 at 9:21 AM
finance.yahoo.com logoLipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
finance.yahoo.com - September 22 at 4:32 PM
MarketBeat logoLipocine (NASDAQ:LPCN) Now Covered by StockNews.com
americanbankingnews.com - September 19 at 3:22 AM
finance.yahoo.com logoLipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance
finance.yahoo.com - September 16 at 3:09 PM
nasdaq.com logoLipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq
nasdaq.com - September 15 at 9:05 AM
benzinga.com logoLipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - Benzinga
benzinga.com - September 15 at 9:05 AM
finance.yahoo.com logoLipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)
finance.yahoo.com - September 15 at 9:05 AM
finance.yahoo.com logoLPCN: TLANDO Launched
finance.yahoo.com - August 10 at 3:47 PM
finance.yahoo.com logoLipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
finance.yahoo.com - August 9 at 7:44 AM
apnews.com logoLipocine: Q2 Earnings Snapshot
apnews.com - August 8 at 9:43 PM
benzinga.com logoRecap: Lipocine Q2 Earnings - Benzinga
benzinga.com - August 8 at 4:43 PM
streetinsider.com logoForm 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.com
streetinsider.com - August 8 at 4:43 PM
seekingalpha.com logoLipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking Alpha
seekingalpha.com - August 8 at 4:43 PM
streetinsider.com logoForm 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
streetinsider.com - August 8 at 4:43 PM
finance.yahoo.com logoLipocine Announces Financial Results for the Second Quarter Ended June 30, 2022
finance.yahoo.com - August 8 at 4:42 PM
nasdaq.com logoS&P 500 Bear Market: Is Now the Right Time to Buy Stocks? - Nasdaq
nasdaq.com - July 11 at 8:47 PM
rttnews.com logoLipocine Says FDA Oks LPCN 2101 IND For Adult Epilepsy Treatment - RTTNews
rttnews.com - July 11 at 3:46 PM
nasdaq.com logoArcutis Says Health Canada Accepts For Review Roflumilast Cream NDS For Plaque Psoriasis - Nasdaq
nasdaq.com - July 11 at 10:18 AM
nasdaq.com logoPrepare to Pay More at Costco for This Reason - Nasdaq
nasdaq.com - July 11 at 10:18 AM
finance.yahoo.com logoLIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS
finance.yahoo.com - June 14 at 12:06 PM
finance.yahoo.com logoLIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE
finance.yahoo.com - June 6 at 8:27 PM
benzinga.com logoLPCN: OLE Results - Benzinga
benzinga.com - May 22 at 8:06 AM
finance.yahoo.com logoLPCN: OLE Results
finance.yahoo.com - May 20 at 3:23 PM
benzinga.com logo4 Stocks Under $3 Insiders Are Aggressively Buying - Benzinga - Benzinga
benzinga.com - May 17 at 12:18 PM
benzinga.com logoLipocine Announces LPCN 1144 NASH Open Label Extension Study Results - Benzinga - Benzinga
benzinga.com - May 13 at 6:41 PM
finance.yahoo.com logoLipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results - Yahoo Finance
finance.yahoo.com - May 13 at 6:41 PM
benzinga.com logoLPCN: First Quarter 2022 Financial and Operational Results - Benzinga
benzinga.com - May 12 at 2:11 PM
finance.yahoo.com logoLipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients
finance.yahoo.com - May 12 at 2:11 PM
finance.yahoo.com logoLipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
finance.yahoo.com - May 12 at 9:10 AM
finance.yahoo.com logoLPCN: First Quarter 2022 Financial and Operational Results - Yahoo Finance
finance.yahoo.com - May 10 at 7:36 PM
finance.yahoo.com logoLipocine Announces Financial Results for the First Quarter Ended March 31, 2022
finance.yahoo.com - May 9 at 12:22 PM
finance.yahoo.com logoLexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update - Yahoo Finance
finance.yahoo.com - May 5 at 1:37 PM
finance.yahoo.com logoShareholders in Lipocine (NASDAQ:LPCN) are in the red if they invested five years ago
finance.yahoo.com - May 4 at 10:40 AM
finance.yahoo.com logoLipocine Inc. (LPCN)
finance.yahoo.com - May 3 at 11:50 PM
benzinga.com logoLipocine Shares Spike; FDA Approves Tlando (testosterone Undecanoate), An Oral Treatment For Testosterone - Benzinga
benzinga.com - April 27 at 9:53 AM
finance.yahoo.com logoFDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc. - Yahoo Finance
finance.yahoo.com - April 26 at 2:34 PM
marketwatch.com logoSubscribers: FDA Approves TLANDO Already Reported - MarketWatch
marketwatch.com - April 25 at 7:41 PM
benzinga.com logoBZ NOTE: News Of FDA Approval Of Lipocine's TLANDO Originally Reported On March 29, Traders Now Circulati - Benzinga
benzinga.com - April 25 at 2:07 PM
finance.yahoo.com logoLIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
finance.yahoo.com - April 11 at 11:25 AM
stocknews.com logo5 Top Stocks Trading Under $2
stocknews.com - March 31 at 11:32 AM
investorplace.com logo7 Undervalued Penny Stocks With Major Upside - InvestorPlace
investorplace.com - March 29 at 11:37 PM
benzinga.com logoLipocine Received FDA Approval for Type 3 - New Dosage Form forTestosterone Undecanoate - Benzinga
benzinga.com - March 29 at 6:36 PM
seekingalpha.com logoTellurian,NeoGenomics, Dave & Buster's Entertainment among premarket losers' pack - Seeking Alpha
seekingalpha.com - March 29 at 8:48 AM
benzinga.com logoUPDATE: Lipocine Sees Commercial Launch Of TLANDO In Q2'22 - Benzinga - Benzinga
benzinga.com - March 29 at 8:48 AM
Get Lipocine News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:LPCN) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.